Lupeng Qiu

机构：Sinovac Biotech, Chinese PLA General Hospital, PLA Academy of Military Science · ORCID：0000-0003-1640-9292

发表论文 15 篇 · 总被引 77 次 · h-index 4

代表论文

• Multi-omics analyses reveal interactions between GREM1+ fibroblasts and SPP1+ macrophages in gastric cancer (2025 · npj Precision Oncology · 被引 19)
• Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients (2020 · Medicine · 被引 18)
• Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters (2023 · BMC Cancer · 被引 14)
• A multicenter, real‐world study on effectiveness and safety of first‐line modified PD ‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer ( aNSCLC ) with drive gene‐negative (2024 · Cancer Medicine · 被引 10)
• Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis (2022 · Frontiers in Oncology · 被引 4)
• Clinical significance and immune landscape of a novel immune cell infiltration-based prognostic model in lung adenocarcinoma (2024 · Heliyon · 被引 2)